



# Mobilizing to address the COVID-19 pandemic

**DELETE TEXT BELOW WITH USAGE INSTRUCTIONS PRIOR TO USE**

- Content last updated: Aug 6, 2020
- These slides are meant to provide a consistent presentation content for external use on our Enterprise response to COVID-19
- This content should be reviewed by your local regulatory, legal, medical and healthcare compliance teams prior to use.

“

**In my 31 years working in healthcare, I have never seen a moment so rich in collaboration, ingenuity and acts of bravery. Public health authorities, private sector companies, research universities, governments and most of all, the heroes on the frontlines of care are mobilizing in ways that current generations have never before witnessed.”**

**Alex Gorsky**

Chairman and Chief Executive Officer

*Johnson & Johnson*



# Mobilizing to address the COVID-19 pandemic



## Developing an investigational vaccine and identifying therapies

We are progressing the development of an investigational vaccine and working with collaborators to identify potential treatments that could provide options to address the current pandemic.



## Supporting frontline healthcare workers

The Johnson & Johnson Family of Companies and the Johnson & Johnson Foundation committed \$50 million to support frontline health workers.



## Taking action to support health equity in communities of color

We are working to advance racial and ethnic health equity in COVID-19 treatment and care through a series of targeted COVID-19 focused programs and partnerships.



## Meeting our commitments to patients and customers

Our global manufacturing network, which produces everything from contact lenses to prescription medications to fever reducers, is currently holding steady and meeting patient needs.



## Caring for our employees

We are supporting the safety, health and well-being of our employees, contractors and the communities in which we live and work.

# We're progressing development of our investigational vaccine and potential treatments and innovative solutions



Collaborating with regulators, healthcare organizations, institutions and communities worldwide to help ensure our research platforms, existing science and outbreak expertise can be maximized to stem this public health crisis.



Our infectious disease experts are providing guidance to entrepreneurs and the startup community embarking on COVID-19 related research and technologies. More than 60 resident companies in our global incubator network Johnson & Johnson Innovation – JLABS are currently exploring novel approaches to help address the COVID-19 pandemic.



Working with global partners to screen a library of molecules, including antivirals, in order to identify potential treatments that could contribute to providing immediate relief to the current pandemic.



Initiated phase 1/2a, a first-in-human clinical study of our investigational vaccine candidate



We are expanding our global capacity to support the goal of supplying more than one billion doses of the vaccine globally.



# Supporting frontline healthcare workers

In March, the Johnson & Johnson Family of Companies and Johnson & Johnson Foundation committed \$50 million to support and supply frontline health workers. This commitment expands upon a \$250 million multi-year commitment made earlier this year to support those at the frontlines guided by the [Johnson & Johnson Center for Health Worker Innovation](#).



## Product donations and volunteering

We have donated millions of J&J products around the world across our Consumer Health, Medical Devices and Pharmaceuticals businesses.



## Delivering essential training, education, supporting mental health and well-being

The Johnson & Johnson Institute developed a COVID-19 Community Hub, to meet some of the pressing needs of healthcare professionals around the world. Doctors, nurses and other clinical and administrative staff visit the Hub for information about managing mental health and well-being and to take courses anytime/anywhere for continuous learning across multiple specialties.



## Fostering advocacy

We are continuing our 120-year legacy of elevating and empowering nurses as innovative, critical leaders on the frontline with a special 10-episode miniseries entitled SEE YOU NOW: COVID-19 The Nurse Response, and a Nurses Innovate QuickFire Challenge aimed at fostering innovative solutions for COVID-19 Patient Care.



## Ensuring connection and integration

To maximize the ability of community health teams to conduct surveillance, contact tracing and tracking and to rapidly deploy high-quality health information to communities and FLHWs through mobile tech, Johnson & Johnson Foundation is supporting a range of mHealth partners: Dimagi, Praekelt.org, mHero, Mothers2Mothers and Reach52.



## Strengthening leadership and management skills

We are supporting the American Organization for Nursing Leadership on the development of leadership and management training for nursing leaders on the frontlines of COVID-19.

# Taking action to support health equity in communities of color



We are establishing **new partnerships** in order to generate deeper, more granular insights to better capture data and understand how the COVID-19 crisis is impacting diverse communities in the US.



We are working directly with many branches of government, as well as partnering with advocates, NGOs and leaders like the Congressional Black Caucus, to lend our voice, expertise and perspective to improving health outcomes in Black communities.



In our Company-sponsored COVID-19 clinical trials, we are **leveraging a special engagement strategy** that includes a digital and community outreach plan to provide resources to help identify opportunities to participate in clinical research, identifying and implementing ways to reduce operational barriers and patient burden, applying lessons from other trial recruitment efforts and educating Black and Hispanic communities across the U.S. about clinical trials and the importance of participation.



# We're working to ensure your access to the Johnson & Johnson medicines, devices and consumer products you depend on

We have robust business continuity plans in place across our global supply chain network to prepare for unforeseen events and to meet the needs of the patients, customers and consumers who depend on our products.

These steps include maintaining critical inventory at major distribution centers away from high-risk areas and working with external suppliers to support our preparedness plans.

## Pharmaceutical

While this remains a dynamic situation, we do not foresee pharmaceutical supply interruptions related to COVID-19 at this time.

## Medical Devices

While this remains a dynamic situation, we are not experiencing significant product supply interruptions related to COVID-19 at this time.

## Consumer Health

We are experiencing increased consumer-driven demand with certain products and in certain markets, which we are currently meeting in a controlled manner. We are taking all possible measures to maximize product availability.

# Caring for our employees

Our employees around the world remain focused on serving our patients, customers and their communities during these challenging times.



**We have directed employees who are able to work from home to do so, and we are ensuring they have the technology available to fulfill their responsibilities.**



**For employees who work in manufacturing, distribution centers, research and development and other important areas that require on-site presence, we have implemented significantly enhanced sanitizing procedures to ensure we maintain safe and well-functioning facilities.**

